Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Promotions
AI
Gate AI
Your all-in-one conversational AI partner
Gate AI Bot
Use Gate AI directly in your social App
GateClaw
Gate Blue Lobster, ready to go
Gate for AI Agent
AI infrastructure, Gate MCP, Skills, and CLI
Gate Skills Hub
10K+ Skills
From office tasks to trading, the all-in-one skill hub makes AI even more useful.
GateRouter
Smartly choose from 40+ AI models, with 0% extra fees
You know what's wild? Regencell Bioscience stock jumped over 21,000% in the past year. Yeah, you read that right. But here's the thing - when you actually dig into what the company does, the whole thing makes zero sense.
Regencell is a China-based biotech focused on traditional Chinese medicine, working on ADHD, autism, and COVID-19 treatments. Sounds interesting on paper. Problem is, they haven't had any real clinical wins to justify that insane valuation. They're pre-commercial, generating zero revenue, consistently unprofitable, yet somehow trading at a $12.8 billion market cap. That's just not normal. The company even warned investors about "substantial doubt" regarding its ability to stay in business. When a stock moves like that without fundamental backing, you're usually looking at short squeezes or pure speculation. Hard pass.
So what's the actual boring alternative? Pfizer. And I know what you're thinking - Pfizer sounds about as exciting as watching paint dry. That's kind of the point.
Pfizer's had a rough stretch. Pandemic products didn't hold up, newer drugs haven't reignited growth, and patent cliffs are coming. Fair criticisms. But the company's pipeline actually looks solid. They've got MET-097i, a GLP-1 candidate that crushed phase 2 trials with strong efficacy and fewer side effects than competitors - plus it's dosed once monthly, which is convenient. They're running phase 3 now. Then there's PF-4404 for cancer. Pfizer launched 11 pivotal studies last year and is planning 20 more. That's real progress.
Beyond the pipeline, Pfizer's been boring in the best way possible. They cut costs through AI-driven efficiency, trading at 8.7x forward earnings versus 18.7x for the healthcare sector average. And if you care about income, they're yielding 6.4% with payouts up 51% over the past decade. Reinvest those dividends and you're compounding wealth quietly.
Regencell is a gamble. Pfizer is a boring compounder that actually has the fundamentals to back it up. Sometimes the most interesting play is the one that puts you to sleep.